Aldosterone (ALDO) may induce cardiac hypertrophy by nonhemodynamic mechanisms that are not completely defined. Cardiotrophin-1 (CT-1) is a cytokine that exerts hypertrophic actions on isolated cardiomyocytes and promotes cardiac hypertrophy in vivo. We investigated whether ALDO induces CT-1 expression in HL-1 cardiomyocytes aiming at the possibility that the cytokine is involved in ALDO-induced cardiomyocyte hypertrophy. mRNA and protein expression were quantified by RT-PCR and Western blot. Cardiomyocyte area, as an index of hypertrophy, was assayed by image analysis in phalloidin-stained HL-1 cells. ALDO addition to adult HL-1 cardiomyocytes increased (P < 0.01) CT-1 mRNA and protein expression in a concentration-dependent manner. This effect was abrogated by actinomycin D, the mineralocorticoid and glucocorticoid receptor antagonists spironolactone and RU486, respectively, and the p38 MAPK blocker SB203580. CT-1 signaling pathway blockade with specific antibodies against the cytokine and its two receptor subunits avoided A CCUMULATING CLINICAL and experimental evidences suggest that aldosterone (ALDO), independently from its hemodynamic effects, participates in the development of left ventricular hypertrophy (LVH) and myocardial remodeling present in cardiac diseases (1). In particular, LVH is specially overstated in subjects with primary hyperaldosteronism, compared with essential or renovascular hypertensive patients, and the presence of LVH is higher in patients with hyperaldosteronism than in essential or renovascular hypertensives, despite similar blood pressure values (2, 3). Plasma ALDO associates with LVH in patients with primary hyperaldosteronism (4, 5) and correlates with both left ventricular mass index and relative wall thickness in untreated essential hypertensives (6). In addition, an excess of plasma ALDO is associated with increased left ventricular wall thickness in normotensive subjects with familial hyperaldosteronism (7).
A CCUMULATING CLINICAL and experimental evidences suggest that aldosterone (ALDO), independently from its hemodynamic effects, participates in the development of left ventricular hypertrophy (LVH) and myocardial remodeling present in cardiac diseases (1) . In particular, LVH is specially overstated in subjects with primary hyperaldosteronism, compared with essential or renovascular hypertensive patients, and the presence of LVH is higher in patients with hyperaldosteronism than in essential or renovascular hypertensives, despite similar blood pressure values (2, 3) . Plasma ALDO associates with LVH in patients with primary hyperaldosteronism (4, 5) and correlates with both left ventricular mass index and relative wall thickness in untreated essential hypertensives (6) . In addition, an excess of plasma ALDO is associated with increased left ventricular wall thickness in normotensive subjects with familial hyperaldosteronism (7) .
Studies in experimental models indicate that ALDO is locally implicated in the development of LVH and myocardial remodeling (8, 9) . Transgenic mice overexpressing 11␤-hydroxysteroid dehydrogenase type 2 in cardiomyocytes, which facilitates ALDO occupancy of mineralocorticoid receptor (MR), exhibit normal blood pressure values but spontaneously develop severe cardiac hypertrophy (10) . Subcutaneous infusion of nonhypertensive doses of ALDO to normotensive rats leads to cardiac hypertrophy independently from blood pressure (11) . Also, in normotensive rats, a high sodium intake for 8 wk produces LVH associated with increased cardiac ALDO production and ALDO synthase overactivity in the absence of blood pressure elevation (12) . However, the molecular and cellular mechanisms underlying the direct hypertrophic effect of ALDO on the heart remain to be established.
Cardiotrophin-1 (CT-1), a cytokine belonging to the IL-6 family, is a 21.5-kDa protein capable of inducing hypertrophy in neonatal and adult cardiomyocytes via its membrane receptor, the heterodimer constituted by the leukemia inhibitory factor receptor (LIFR) and the glycoprotein 130 (gp130) (13) (14) (15) . Intraperitoneal administration of recombinant CT-1 to normotensive mice increases left ventricular weight in a dose-dependent manner (16) . Cardiac CT-1 expression is increased in several experimental models of hypertensive LVH (15, 17, 18) . Furthermore, plasma levels of CT-1 are increased in hypertensive patients with LVH and decrease after antihypertensive therapy only in patients exhibiting LVH regression (19, 20) . Of interest, it has been reported that some humoral factors classically involved in LVH development stimulate CT-1 expression (21) (22) (23) .
We hypothesized that a mechanism for ALDO to induce cardiomyocyte hypertrophy may be the induction of CT-1 expression in these cells. To test this possibility, we first investigated whether ALDO was able to induce CT-1 expression and the intracellular pathways involved in this effect in HL-1 adult cardiomyocytes. Second, we analyzed the hypertrophic effects of ALDO in conditions of CT-1-pathway blockade in the same cell line. Finally, we approached the in vivo relevance of these data assaying the induction of cardiac CT-1 mRNA and hypertrophic genes in response to an acute ALDO overloading in C57BJ6 wild-type and CT-1-null mice.
Materials and Methods

Cell culture
HL-1, a cell line derived from adult mouse heart (24), were a gift from Dr. W. C. Claycomb 
Measurement of cell size
HL-1 cardiomyocytes grown on glass coverslips were fixed in 4% formaldehyde, and stained with Alexa Fluor 488-conjugated phalloidin (Molecular Probes, Invitrogen) (1:50 dilution) for 30 min at 37 C to visualize F-actin. Cell surface area from at least 50 cardiomyocytes per condition was measured in three independent experiments using the automated image analysis system (Soft Imaging Analysis, Mü nster, Germany).
Animals
The investigation was performed in accordance with the Guide for Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (publication no. 82-23, revised in 1996). CT-1-null mice were a gift from Dr. M. Selzner (Zurich University Hospital, Zurich, Switzerland). Although cardiac characterization of this strain has not been reported, in our experience, at the age of 5 months, these mice do not spontaneously develop cardiac hypertrophy because they exhibit similar left ventricular morphometry (i.e. wall thickness and chamber diameter), similar cardiomyocyte diameter, and similar expression of ANP and c-fos genes than their wild-type background (our unpublished data). Male C57BJ6 wild-type mice (5 months old) and age-matched CT-1-null mice received one ip injection of ALDO 1 mg/kg or vehicle (150 mmol/liter NaCl, 5% ethanol) (n ϭ 8, each group). Two hours after the injection, blood samples were obtained from the half of the animals (n ϭ 4 each group) to measure plasma ALDO concentration by RIA (Diasorin, Saluggia, Vercelli, Italy). To avoid hemodynamic effects of the mineralocorticoid, animals were killed 6 h after the injection by cervical dislocation under 3% isoflorane anesthesia. Hearts were removed, weighed, and immediately frozen in liquid nitrogen for molecular studies.
Western blotting
Aliquots of 20 g of proteins were size fractionated on 15% (for CT-1) or 10% (for c-fos and ␣-sarcomeric actin) polyacrylamide gels by electrophoresis and transferred to polyvinyl difluoride membranes. The following specific antibodies were used diluted at 1:500: CT-1 (Santa Cruz Biotechnology), p38, p38-P (Thr180/Tyr182; Cell Signaling Technology, Danvers, MA), MR, and GR (Abcam, Cambridge, MA). Western blots were also stained for ␤-actin (Sigma) diluted at 1:1000 to correct for protein loading. In all cases, bound antibody was detected by peroxidase-conjugated secondary antibodies (Amersham Biosciences, Piscataway, NJ) and visualized using the ECL-Plus chemiluminescence detection system (Amersham Biosciences). After densitometry, OD values were expressed as arbitrary units. All Western blots were performed at least in triplicate for each animal or in vitro experimental condition.
Reverse transcription and real-time PCR
Total RNA was extracted from cells and hearts using Trizol (Invitrogen) and subsequently purified using RNeasy total RNA isolation kit (QIAGEN, Milden, Germany). Reverse transcription was performed with 500 ng of total RNA. Real-time PCR was performed with an ABI Prism 7000 sequence detection system (Applied Biosystems Inc., Foster City, CA) by using specific TaqMan MGB fluorescent probes (Applied Biosystems) for mice CT-1, ANP, and c-fos. All samples were assayed in triplicate and normalized on the basis of their constitutive 18S ribosomal RNA. To detect the expression of GR and MR in the HL-1 cell line, mRNA was retrotranscripted, and the following specific primers recently reported by Sierra et al. (25) were used: 5Ј-TGC TAT GCT TTG CTC CTG ATC TG-3Ј and 5Ј-TGT CAG TTG ATA AAA CCG CTG CC-3Ј for GR and 5Ј-GTG GAC AGT CCT TTC ACT ACC G-3Ј and 5Ј-TGA CAC CCA GAA GCC TCA TCT C-3Ј for MR.
Statistical analysis
Results are presented as mean Ϯ se and computed from the average measurements obtained from each experimental condition or from each group of animals. Normal distribution of data were checked by means of the Shapiro Wilks test. A Levene statistic test was performed to check the homogeneity of variances. The unpaired Student's t test or the Mann Whitney U tests were used to assess statistical differences between the two experimental groups. Differences among more than two experimental conditions were tested by the ANOVA one-way test followed by the Scheffé test to analyze differences between groups. P Ͻ 0.05 was considered significant.
Results
ALDO induces CT-1 up-regulation in HL-1 cardiomyocytes
Incubation of HL-1 with ALDO (10 Ϫ9 to 10 Ϫ6 mol/liter) for 3 or 24 h increased (P Ͻ 0.01) CT-1 mRNA and protein, respectively, in a concentration-dependent manner (Fig. 1, A and B). Time-course examination showed that early induction of CT-1 mRNA levels by ALDO peaked at 2.3-fold (P Ͻ 0.01) after 3 h. For longer periods, the increase in CT-1 mRNA was stable at around an 80%. The increase in CT-1 protein expression accounted progressively and later than mRNA increase (Fig. 1C) . To evaluate whether CT-1 increase was a direct effect of ALDO or whether it involved the synthesis of intermediary proteins, we analyzed the effects of transcription and transduction inhibitors on ALDO-induced CT-1 upregulation. The transcription inhibitor actinomycin D completely inhibited (P Ͻ 0.01) the increase of CT-1 mRNA and protein induced by ALDO, whereas the protein synthesis inhibitor cycloheximide did not affect CT-1 mRNA and completely blunted (P Ͻ 0.01) the protein induction (Fig. 2, A and  B) . Before investigating the involvement of MR and GR in this effect, we performed specific experiments to confirm that this cell type expressed the two steroid receptors. As shown in Fig. 2C , conventional PCR allowed the detection of MR and GR mRNA in HL-1 cardiomyocytes. Because ALDO binds MR and GR with different affinity, low hormone concentrations will bind MR and high concentrations will also bind GR. Moreover, receptor antagonists are usually used at 10-to 100-fold excess to ensure an effective blockade. Thus, to investigate the role of MR and GR, cells were preincubated for 30 min with spironolactone and/or RU486 at 10 Ϫ6 mol/ liter, and ALDO was added at 10 Ϫ8 or 10 Ϫ7 mol/liter. Prior addition of the specific MR and/or the GR blocker to HL-1 culture abolished (P Ͻ 0.01) ALDO-induced CT-1 up-regulation (Fig. 2, C and D) , indicating that both receptors may mediate CT-1 induction. In additional experiments, we confirmed that the GR agonist dexamethasone used at 10 Ϫ6 mol/liter was able to induce 2-fold the synthesis of CT-1 protein (data not shown). None of the chemical inhibitors tested in these experiments affected CT-1 expression when incubated alone (data not shown).
Once established that CT-1 up-regulation was a genomic effect of ALDO, we investigated the potential participation of other intracellular cascades that ALDO activates in cardiac cells, by the use of specific chemical inhibitors. As illustrated in Fig. 3 , the p38 MAPK inhibitor SB203580 completely abolished (P Ͻ 0.01) the induction of CT-1 expression, whereas the p42/44 MAPK inhibitor PD98059 and the calcium L-type channel antagonist lercanidipine did not modify CT-1 expression induced by ALDO (Fig. 3, A and B) . None of the chemicals tested affected CT-1 expression when incubated alone (data not shown). Because p38 MAPK is one of the signaling pathways used by ALDO to exert rapid nongenomic effects (26, 27) , we next studied whether p38 MAPK activation occurred independently or downstream from ALDO-MR binding. A time-response analysis of ALDO-induced p38 MAPK activation demonstrated a significant 2-to 3.5-fold activation (P Ͻ 0.01) from 30 min to 3 h of incubation. Additionally, whereas p38 phosphorylation induced by ALDO was not affected by spironolactone at the first 30 min, the MR blocker inhibited this effect up to 3 h (Fig. 3C) . These findings indicate that ALDO-induced p38 MAPK activation in HL-1 involves early MR-independent mechanisms followed by MR-dependent pathways.
CT-1 is involved in HL-1 hypertrophy induced by ALDO
We next investigated the hypertrophic effect of ALDO on HL-1 cardiomyocytes and the potential involvement of CT-1 in this effect. As shown in Fig. 4 , ALDO addition to HL-1 induced a significant increase (P Ͻ 0.01) in ␣-sarcomeric actin and c-fos protein expression in 24 h and promoted a significant (P Ͻ 0.01) cell area enlargement in 48 h. Prior addition of specific antibodies against each of the two CT-1 receptor subunits, gp130 and LIFR, or against CT-1 to the culture medium abolished (P Ͻ 0.01) the increase in cell area and the overexpression of hypertrophic proteins induced by the mineralocorticoid. None of the three antibodies exerted any effect when incubated alone (data not shown).
ALDO acutely induces the expression of cardiac hypertrophic genes in wild-type but not in CT-1-null mice
To investigate whether our observations in HL-1 cardiomyocytes also accounted in vivo, we performed an experiment of ALDO acute overloading in mice to analyze cardiac mRNA expression of CT-1 and hypertrophic genes. In wildtype mice C57BJ6, a single ip injection of ALDO (1 mg/kg) resulted in a significant increase (P Ͻ 0.01) of myocardial CT-1 mRNA expression, compared with mice injected with vehicle. As expected, this response was not observed in CT-1-null mice (Fig. 5A) . Interestingly, the single bolus of the mineralocorticoid resulted in a significant (P Ͻ 0.01) cardiac overexpression of ANP and c-fos genes in wild-type mice, compared with those that received vehicle, whereas no changes in the expression of these genes were observed in the myocardium of CT-1-null mice (Fig. 5, B and C) . The degree of elevation in serum ALDO concentration after the hormone injection was similar in the two strains of mice (ϫ 940 in wild-type and ϫ 1145 in CT-null mice). 
Discussion
The major findings presented in this study are: 1) ALDO induces CT-1 expression in HL-1 adult cardiomyocytes via MR and GR and through the activation of p38-MAPK signaling pathway, 2) CT-1 pathway blockade with specific antibodies avoids ALDO-induced hypertrophy in this cell line, 3) exogenously administrated ALDO induces myocardial CT-1 expression and a genetic pattern of hypertrophy in C57BJ6 wild-type mice, and 4) this genetic pattern is absent in CT-1-null mice subjected to the same maneuver.
Although a number of findings suggest a role for ALDO in LVH, it is difficult to distinguish between the direct actions of the hormone on the myocardium and those secondary to blood pressure elevation induced by the mineralocorticoid. Only two studies have reported direct hypertrophic effects of ALDO on cardiomyocytes (28, 29) . The two molecular mechanisms proposed to explain ALDO-induced cardiomyocyte hypertrophy agree in the involvement of MR and differ in the downstream intracellular intermediates that are involved. Whereas Na ϩ /H ϩ exchanger type 1 activation seems to be crucial to cell-size increase promoted by ALDO in neonatal ventricular cardiomyocytes (29) , activation of the intracellular intermediates protein kinase C-␣, p42/44, and c-Jun Nterminal kinase MAPKs precedes the increase of the sarcomeric proteins ␣-and ␤-myosin in the same model (28) . Present data showing that ALDO induces CT-1 expression in HL-1 cardiomyocytes, together with the observation that CT-1 pathway blockade avoids both ␣-sarcomeric actin and c-fos protein overexpression, and the cell area enlargement induced by the hormone, suggest a new molecular mechanism to explain ALDO-induced hypertrophy in adult cardiomyocytes. The in vivo relevance for this mechanism is sup- ported by the finding that CT-1-null mice are unable to acutely increase ANP and c-fos myocardial expression in response to acute ALDO overloading as observed in the wild-type mice. Of importance, our observations in mice do not allow to exclude the possibility that both myocardial cell types, cardiomyocytes and cardiac fibroblasts, participate in cardiac CT-1 up-regulation observed in vivo. In this regard, preliminary data from our laboratory revealed that ALDO induces mRNA and protein expression of CT-1 in adult cardiomyocytes and fibroblasts freshly isolated from adult Wistar rats (our unpublished data). Ongoing studies will clarify the real role of this autocrine/paracrine mechanism in ALDO-associated cardiac hypertrophy that accounts in pathological conditions. Classic genomic effects of ALDO are characterized by a latency of onset and their sensitivity to mRNA and protein synthesis inhibitors. Our results showing the time course of CT-1 mRNA increase and the inhibition exerted by actinomycin D on mRNA and protein increase clearly demonstrate that the induction of CT-1 expression is a new genomic effect of the mineralocorticoid in cardiomyocytes. Moreover, the observation that the transduction blocker cycloheximide does not affect the CT-1 mRNA increase induced by ALDO indicates that this is a direct primary effect that does not require the synthesis of intermediate proteins.
Regarding the receptor involved in this effect, our results indicate that both MR and GR are able to mediate the CT-1 up-regulation induced by ALDO. Previous in vitro studies have reported ALDO primary genomic effects partially or completely mediated by GR in epithelial (30) and nonepithelial cells (31, 32) . ALDO, as well as glucocorticoids, is able to bind GR and MR with the affinity being 100-fold higher for MR than GR (33) . It is well established that the two types of steroid receptors share structural and functional homology, and both are transcription factors in cardiomyocytes (34 -36) . In this study, homology searchers of the CT-1 promoter region for transcription factors binding elements by means of the Transfact Produktion-Planung-Steurung (PPS) software (Transfact Industrial Software & Engineering, Heikendorf, Germany) led us to identify at least two putative steroid response elements located at around 0.9 and 1.3 kb upstream from the transcription start site. Thus, it is reasonable to hypothesize that, at least in vitro, either MR-or GRligand complexes might bind these target sites to induce CT-1 expression. Concerning the in vivo context, recent studies in the field of MR vs. GR specificity in cardiovascular corticosteroids actions indicate that the importance of MR signaling is controlled at two levels. First, it is controlled by prereceptor mechanisms, i.e. mineralocorticoids/glucocorticoids proportion, which is mainly determined by the expression 11␤-hydroxysteroid dehydrogenase 2 and the endogenous synthesis of ALDO in cardiovascular tissues (37) . Second, it has been recently proposed that the intracellular context, i.e. redox state of the cell, may resolve activation of MR-dependent signals by glucocorticoids (38, 39) . Hence, further studies are required to determine the precise corticosteroid signaling pathway that may intervene in this response in pathophysiological conditions.
Increasing evidence indicates that, besides the classical MR-dependent genomic actions, ALDO exerts a set of rapid nongenomic effects via MR-dependent and/or MR-independent mechanisms (40, 41) . Furthermore, despite details of the mineralocorticoid signaling are missing, available data indicate that a cross talk between genomic and nongenomic activities may be the key for understanding the real significance of mineralocorticoids in the cardiovascular system (41, 42) . Hence, rapid activation of protein kinase-C induced by ALDO is necessary for a subsequent genomic effect of the hormone, i.e. induction of Na ϩ /K ϩ -ATPase expression, in renal cells (43) . Similarly, activation of c-Src tyrosine kinase and endothelial growth factor receptor transactivation are two rapid MR-mediated effects that support the following ALDO-induced endothelial growth factor receptor overexpression in several cell lines (44). Callera et al. (26) reported that ALDO-induced activation of c-Src and succeeding p38 MAPK phosphorylation are two nongenomic events mediating the subsequent fibrogenic effect of the mineralocorticoid in freshly isolated aortic vascular smooth muscle cells. Here we tested the involvement of nongenomic mechanisms in the increase of CT-1 mRNA by analyzing the three rapid signaling pathways that ALDO activates in cardiac cells: p38 and p42/44 MAPK, and L-type calcium channels (28, 29, 45, 46) . Among the chemical blockers tested, only the p38 MAPK inhibitor abrogated ALDO-induced CT-1 expression (Fig. 3) , suggesting a determinant role for this MAPK in this genomic effect of ALDO. This finding is in accordance with results previously reported demonstrating the involvement of p38 MAPK on ALDO-induced connective tissue growth factor up-regulation in cardiac cells (46) . Furthermore, several data presented here reinforce the possibility that ALDO-induction of CT-1 is mediated by the cross talk of early nongenomic mechanisms that support following genomic pathways. On the one hand, ALDO increases p38 MAPK phosphorylation via MR-independent and -dependent pathways without modifying the expression of nonphosphorylated p38 MAPK, On the other hand, the time-course analysis of p38 phosphorylation and CT-1 mRNA up-regulation suggests that the first precedes the increase of cytokine expression induced by ALDO. Thus, regarding the stage of the knowledge in mineralocorticoid signaling, this study adds to a novel example of cross talk between nongenomic and genomic signals that may clarify the mechanisms by which ALDO induces hypertrophy in cardiac cells.
In summary, findings here presented suggest that cardiac CT-1 may be up-regulated by ALDO through mechanisms that involve MR and GR and the cross talk between rapid nongenomic and genomic mechanisms. Furthermore, ALDO-induced CT-1 up-regulation seems to play a role in the ability of the mineralocorticoid to produce cardiomyocyte growth, and, as a result, cardiac hypertrophy. The potential clinical relevance of these findings is based on the association between increased CT-1 and LVH observed in essential hypertensives (19, 20) as well as the association of increased CT-1 and left ventricular dysfunction reported in patients with heart failure (47-49), thus setting the stage for studies aimed to test the effects of MR antagonists on CT-1.
